Dynavax Technologies Corporation Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (50)

Latest Posts

About This Stock More About This Stock
Best Pharmaceutical Stocks To Buy In 2021
Article By: Elliottwave Forecast
Wednesday, October 6, 2021 5:16 AM EDT
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S. dollars.
In this article: BMY, GSK, JNJ, PFE, DVAX, ABBV
Read
Notable Insider Buys: Avis, Dynavax, And Formula One
Article By: Benzinga
Sunday, May 31, 2020 4:44 PM EDT
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason: they believe the stock price will rise and they want to profit from it. So, insider buying can be an encouraging signal for potential investors.
In this article: CAR, DVAX, FWONA Also: BRK-A, GDOT, HTZZ, RCL, JAZZ, MRSN
Read
Week In Review: Abbisko Raises $70 Million To Develop Cancer Drug Candidates
Article By: ChinaBio® Today
Saturday, March 28, 2020 3:03 PM EDT
Shanghai Abbisko Therapeutics raised $70 million in a Series C financing to develop its portfolio of small molecule targeted oncology and immuno-oncology candidates.
In this article: SRNE, DVAX
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA
Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
5 Of The Best-Performing Biotech Stocks Of 2017
Article By: Arpita Dutt
Sunday, December 31, 2017 3:46 PM EDT
2017 turned out to be a pretty good year for the biotech sector. The sector had been struggling due to the drug pricing controversy, mixed results, slower-than-expected new product launches, increasing competition and pipeline setbacks.
In this article: XOMA, DVAX, SGMO, ALNY, BLUE, PFE, GILD
Read

Latest Tweets for $DVAX

No tweets yet!

PARTNER HEADLINES